Oppenheimer Initiates Coverage On Sutro Biopharma with Outperform Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has initiated coverage on Sutro Biopharma (NASDAQ:STRO) with an Outperform rating and a price target of $10.
October 06, 2023 | 9:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Sutro Biopharma with an Outperform rating and a price target of $10, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Oppenheimer's Outperform rating and $10 price target for Sutro Biopharma suggest a positive outlook for the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100